Concord Biotech has been granted final approval from the United States Food and Drug Administration (USFDA) for marketing its Teriflunomide Tablets, 7 mg and 14 mg. Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.
This approval reinforces the company’s capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market. According to IQVIA, the market size of Teriflunomide tablets is around $402 million in the US, and the global market size is around $908 million, indicating significant opportunities for expansion in the US and the global market.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.20 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 923.10 |
| Lupin | 2312.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: